Exciting News To Come22 Jul 2020 13:06
And COVIDITY still a very live candidate........................
None of the Placing, the Open Offer or the Subscription are underwritten.
The net proceeds from the Capital Raise, in addition to the Company's existing cash resources and anticipated tax credits, will be used to:
· strengthen the Company's balance sheet to support potential partnering discussions for the Company's antibody technology;
· support clinical trials for Modi-1 Phase 1/2 and SCIB1 Phase 2; and
· continue initial COVID-19 vaccine development until non-dilutive funding or third-party partnering transaction.